AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6344611 — intervention group
Group type: EXPERIMENTAL
Intervention: Galactose
Number of subjects: 20
Study 6344611 — intervention group
Group type: EXPERIMENTAL
Intervention: Water alone
Number of subjects: 20
Study 29920980 — intervention group
Group type: EXPERIMENTAL
Intervention: Bapineuzumab (5 mg, 10 mg, 20 mg, 40 mg, 80 mg)
Number of subjects: 40
Study 30120529 — intervention group
Group type: EXPERIMENTAL
Intervention: FemoSeal™
Number of subjects: 155
Study 30120529 — intervention group
Group type: COMPARATOR
Intervention: Perclose ProGlide®
Number of subjects: 155
Study 27314581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified biscuits with heme iron concentrate (n = 15)
Number of subjects: 47
Study 27314581 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified biscuits with iron sulfate (n = 19)
Number of subjects: 47
Study 27314581 — intervention group
Group type: COMPARATOR
Intervention: Control group (biscuit control group, n = 13)
Number of subjects: 47
Study 25166750 — intervention group
Group type: EXPERIMENTAL
Intervention: 3000 IU of oral cholecalciferol daily for 4 months
Number of subjects: 40
Study 25166750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22008309 — intervention group
Group type: EXPERIMENTAL
Intervention: IV acetaminophen
Number of subjects: 101
Study 22008309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 19293312 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1B1 haplotype-tagging single nucleotide polymorphisms (rs9341266)
Number of subjects: 3125
Study 19293312 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP1B1 haplotypes
Number of subjects: 3125
Study 19293312 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 3125
Study 17599630 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide 0.1 microg/kg
Number of subjects: 40
Study 17599630 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide 1 microg/kg
Number of subjects: 40
Study 17599630 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide 10 microg/kg
Number of subjects: 40
Study 17599630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17599630 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide (any dose)
Number of subjects: 40
Study 17599630 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-galactosylceramide (1 patient, non-responder)
Number of subjects: 40
Study 14701781 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (7.5 mg orally every 12 hours and 5 mg every 4 hours as needed)
Number of subjects: 103
Study 14701781 — intervention group
Group type: COMPARATOR
Intervention: Morphine (15 mg sustained release every 12 hours and 5 mg every 4 hours as needed)
Number of subjects: 103
Study 14701781 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 103
Study 14701781 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 103
Study 14701781 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Methadone and Morphine
Number of subjects: 103
Study 11602266 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the Resident Assessment Instrument (RAI)
Number of subjects: 0
Study 11602266 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10396343 — intervention group
Group type: EXPERIMENTAL
Intervention: TrypTect CIATT
Number of subjects: 164
Study 10396343 — intervention group
Group type: COMPARATOR
Intervention: Melarsoprol treatment
Number of subjects: 164
Study 10396343 — intervention group
Group type: EXPERIMENTAL
Intervention: ELISA
Number of subjects: 164
Study 7978143 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propofol infusion while breathing 100% oxygen
Number of subjects: 80
Study 7978143 — intervention group
Group type: COMPARATOR
Intervention: Inhalational nitrous oxide, oxygen and halothane for maintenance of anaesthesia
Number of subjects: 80
Study 2913769 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 14
Study 2913769 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 14
Study 31116277 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA only (MTA group)
Number of subjects: 45
Study 31116277 — intervention group
Group type: EXPERIMENTAL
Intervention: CH with saline (CH+saline group)
Number of subjects: 45
Study 31116277 — intervention group
Group type: EXPERIMENTAL
Intervention: CH with polyethylene glycol (CH+PEG group)
Number of subjects: 45
Study 27824253 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 ml of radiolabeled (1 mCi 99mTc-DTPA) universal placebo, hydroxyethyl cellulose gel
Number of subjects: 8
Study 27824253 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of radiolabeled (1 mCi 99mTc-DTPA) universal placebo, hydroxyethyl cellulose gel
Number of subjects: 8
Study 25926088 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (2,500 U)
Number of subjects: 490
Study 25926088 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin (5,000 U)
Number of subjects: 490
Study 23563076 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Resilience Enhancement Program (FREP), 10 sessions over 5 weeks
Number of subjects: 34
Study 23563076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 34
Study 21764398 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage condition
Number of subjects: 49
Study 21764398 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 49
Study 19218138 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphocreatine treatment (8 weeks)
Number of subjects: 40
Study 19218138 — intervention group
Group type: COMPARATOR
Intervention: Basic treatment (control group)
Number of subjects: 40
Study 17031010 — intervention group
Group type: EXPERIMENTAL
Intervention: VF crispy bar
Number of subjects: 60
Study 17031010 — intervention group
Group type: COMPARATOR
Intervention: Commercial crispy bars
Number of subjects: 60
Study 12857504 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP
Number of subjects: 30
Study 12857504 — intervention group
Group type: COMPARATOR
Intervention: IPPV
Number of subjects: 30
Study 12857504 — intervention group
Group type: EXPERIMENTAL
Intervention: SIMV
Number of subjects: 30
Study 10763145 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CMF chemotherapy
Number of subjects: 684
Study 10763145 — intervention group
Group type: COMPARATOR
Intervention: Observation only
Number of subjects: 684
Study 8988450 — intervention group
Group type: EXPERIMENTAL
Intervention: African American patients
Number of subjects: 272
Study 8988450 — intervention group
Group type: EXPERIMENTAL
Intervention: White patients
Number of subjects: 272
Study 1348777 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 0
Study 1348777 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3904436 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam at a dosage greater than 200 mg per day
Number of subjects: 1800
Study 3904436 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam at 200 mg per day
Number of subjects: 1800
Study 3904436 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered aspirin at 3,600 to 4,800 mg per day
Number of subjects: 1800
Study 3904436 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin at 150 mg per day
Number of subjects: 1800
Study 3904436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1800
Study 3904436 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered aspirin
Number of subjects: 1800
Study 3904436 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 1800
Study 3904436 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoxicam
Number of subjects: 1800
Study 31166081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil 60 mg
Number of subjects: 60
Study 31166081 — intervention group
Group type: COMPARATOR
Intervention: Fasudil 30 mg
Number of subjects: 60
Study 30307816 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous solution containing betaine, zinc and polyhexamethylene biguanide (polihexanide)
Number of subjects: 260
Study 30307816 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% saline solution containing 0.2% sodium hypochlorite
Number of subjects: 260
Study 30307816 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 260
Study 30307816 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation solution containing sea salt 1.2% and NaOCl 0.4%
Number of subjects: 260
Study 30307816 — intervention group
Group type: COMPARATOR
Intervention: Sterile 0.9% saline
Number of subjects: 260
Study 28195010 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal smoking cessation intervention (brief motivational interview and self-help material during hospitalization, followed by a 4-month pharmacological and psychosocial intervention post-discharge)
Number of subjects: 754
Study 28195010 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal smoking cessation intervention
Number of subjects: 754
Study 28195010 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 754
Study 24382109 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally Adapted Cognitive Behaviour Therapy for Psychosis (CaCBTp)
Number of subjects: 42
Study 24382109 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 42
Study 24279026 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation technology (group A)
Number of subjects: 8
Study 24279026 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric knife (group B)
Number of subjects: 8
Study 24279026 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalpel (group C)
Number of subjects: 8
Study 24279026 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group D, control)
Number of subjects: 8
Study 21262590 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of combined oral estroprogestins (CON)
Number of subjects: 57
Study 21262590 — intervention group
Group type: COMPARATOR
Intervention: Cyclic administration of combined oral estroprogestins (CYC)
Number of subjects: 57
Study 18500097 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-optimized LASIK
Number of subjects: 374
Study 18500097 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 374
Study 16488356 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT (Systolic Hypertension in Europe trial)
Number of subjects: 0
Study 16488356 — intervention group
Group type: EXPERIMENTAL
Intervention: GPRD study (simulated Systolic Hypertension in Europe trial)
Number of subjects: 0
Study 16488356 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended GPRD study
Number of subjects: 0
Study 12698853 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxocycline (DC) 200 mg/day
Number of subjects: 79
Study 12698853 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (EM) 2 g/day
Number of subjects: 79
Study 12698853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CF) 1 g/day
Number of subjects: 79
Study 12698853 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (CT) 1920 mg/day
Number of subjects: 79
Study 11132912 — intervention group
Group type: EXPERIMENTAL
Intervention: TrocDoc
Number of subjects: 62
Study 11132912 — intervention group
Group type: COMPARATOR
Intervention: Veress needle/first trocar
Number of subjects: 62
Study 11132912 — intervention group
Group type: COMPARATOR
Intervention: Hasson trocar
Number of subjects: 62
Study 9080151 — intervention group
Group type: EXPERIMENTAL
Intervention: External high-frequency oscillation ventilation for 4 hours, then positive pressure ventilation for 1 hour
Number of subjects: 24
Study 9080151 — intervention group
Group type: COMPARATOR
Intervention: Intermittent positive pressure ventilation throughout the observation period (5 hours)
Number of subjects: 24
Study 8365932 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 Gy hepatic irradiation
Number of subjects: 173
Study 8365932 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy hepatic irradiation
Number of subjects: 173
Study 8365932 — intervention group
Group type: EXPERIMENTAL
Intervention: 33 Gy hepatic irradiation
Number of subjects: 173
Study 8365932 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressively higher total doses of hepatic irradiation
Number of subjects: 173
Study 3521717 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir tablets (400 mg) administered five times daily
Number of subjects: 60
Study 3521717 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir ophthalmic ointment administered five times daily
Number of subjects: 60
Study 29423520 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-RT (Cisplatin Chemoradiotherapy)
Number of subjects: 850
Study 29423520 — intervention group
Group type: COMPARATOR
Intervention: RT (Radiotherapy)
Number of subjects: 850
Study 27500338 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350 (PEG3350)
Number of subjects: 145
Study 27500338 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert)
Number of subjects: 145
Study 24646311 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3050
Study 24646311 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3050
Study 24646311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3050
Study 24646311 — intervention group
Group type: EXPERIMENTAL
Intervention: GAD autoantibody positivity
Number of subjects: 3050
Study 24646311 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulinoma‐associated‐2 autoantibodies
Number of subjects: 3050
Study 23262213 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based biosecurity intervention involving community education and hygiene practices.
Number of subjects: 749
Study 22039251 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised grading criteria using annual stereoscopic color fundus photographs and fluorescein angiograms
Number of subjects: 114
Study 22039251 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of two imaging modalities (color photographs and fluorescein angiograms)
Number of subjects: 114
Study 18481719 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular point sticking combined with Tongshiji treatment
Number of subjects: 300
Study 18481719 — intervention group
Group type: COMPARATOR
Intervention: Simple Tongshiji treatment (control group)
Number of subjects: 300
Study 16549945 — intervention group
Group type: EXPERIMENTAL
Intervention: EBC collection without a nose clip
Number of subjects: 40
Study 16549945 — intervention group
Group type: COMPARATOR
Intervention: EBC collection with a nose clip
Number of subjects: 40
Study 12624851 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA) group
Number of subjects: 36
Study 12624851 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) group
Number of subjects: 36
Study 10745287 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet counselling on protein restriction for 12 months
Number of subjects: 125
Study 10745287 — intervention group
Group type: COMPARATOR
Intervention: Usual dietary advice (control group)
Number of subjects: 125
Study 9185751 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 126
Study 9185751 — intervention group
Group type: COMPARATOR
Intervention: Control (no EVL)
Number of subjects: 126
Study 1587377 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy utilizing the husband's lymphocytes
Number of subjects: 1120
Study 1587377 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppressant and anticoagulant therapy
Number of subjects: 1120
Study 1587377 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling and ideal metroplasty
Number of subjects: 1120
Study 1587377 — intervention group
Group type: COMPARATOR
Intervention: Immunotherapy indicated but not received
Number of subjects: 1120
Study 2876719 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion (0.4 to 0.5 micrograms kg‐1 min‐1)
Number of subjects: 30
Study 2876719 — intervention group
Group type: COMPARATOR
Intervention: Pethidine infusion
Number of subjects: 30
Study 2876719 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil infusion
Number of subjects: 30
Study 31554490 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green angiography
Number of subjects: 37
Study 29523108 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailing of a second reminder and a self-sampling kit
Number of subjects: 9791
Study 29523108 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailing of a second reminder that offered a self-sampling kit to be ordered by e-mail, text message, phone, or webpage
Number of subjects: 9791
Study 29523108 — intervention group
Group type: COMPARATOR
Intervention: Mailing of a second reminder to attend regular cytology screening
Number of subjects: 9791
Study 26558600 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Protein Maize (QPM)
Number of subjects: 61
Study 26558600 — intervention group
Group type: COMPARATOR
Intervention: Conventional maize
Number of subjects: 61
Study 24139824 — intervention group
Group type: EXPERIMENTAL
Intervention: CaD (700 mg calcium + 200 IU vitamin D)
Number of subjects: 176
Study 24139824 — intervention group
Group type: EXPERIMENTAL
Intervention: CaDEA (700 mg calcium + 200 IU vitamin D + 12 IU vitamin E + 2,000 IU vitamin A)
Number of subjects: 176
Study 24139824 — intervention group
Group type: COMPARATOR
Intervention: Ca (700 mg calcium)
Number of subjects: 176
Study 22420668 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR assay
Number of subjects: 100
Study 22420668 — intervention group
Group type: EXPERIMENTAL
Intervention: Method C (including episodes of possible IFI as true positive)
Number of subjects: 100
Study 22420668 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR
Number of subjects: 100
Study 20015056 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate/NBUVB phototherapy (group A)
Number of subjects: 40
Study 20015056 — intervention group
Group type: COMPARATOR
Intervention: Placebo/NBUVB phototherapy (group B)
Number of subjects: 40
Study 20015056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17888202 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate (300 microg/d)
Number of subjects: 0
Study 17888202 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched yeast (300 microg/d)
Number of subjects: 0
Study 17888202 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium-enriched milk (480 microg/d)
Number of subjects: 0
Study 17888202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17888202 — intervention group
Group type: EXPERIMENTAL
Intervention: All selenium sources
Number of subjects: 0
Study 17888202 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenate
Number of subjects: 0
Study 17888202 — intervention group
Group type: EXPERIMENTAL
Intervention: Organic forms (Se-enriched yeast and Se-enriched milk)
Number of subjects: 0
Study 19616498 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV), three doses
Number of subjects: 0
Study 19616498 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV), two doses
Number of subjects: 0
Study 19616498 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV), one dose
Number of subjects: 0
Study 15791443 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc‐granulocytes (approximately 200 MBq) and 111In‐granulocytes (approximately 0.5 MBq)
Number of subjects: 30
Study 15791443 — intervention group
Group type: COMPARATOR
Intervention: Whole-body 111In retention (WBR)
Number of subjects: 30
Study 11480806 — intervention group
Group type: EXPERIMENTAL
Intervention: Definite/Etch & Prime 3.0 (D‐EP)
Number of subjects: 52
Study 11480806 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitaire/Solid Bond (S‐SB)
Number of subjects: 52
Study 11480806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both materials (D‐EP and S‐SB)
Number of subjects: 52
Study 9497213 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation therapy (EVL)
Number of subjects: 59
Study 9497213 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection variceal sclerotherapy (EVS)
Number of subjects: 59
Study 9497213 — intervention group
Group type: COMPARATOR
Intervention: Combination of EVL plus low-dose EVS
Number of subjects: 59
Study 7961545 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine (75 to 375 mg/day)
Number of subjects: 2000
Study 7961545 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine (higher dosages)
Number of subjects: 2000
Study 7961545 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine
Number of subjects: 2000
Study 7961545 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine (200 mg/day)
Number of subjects: 2000
Study 7961545 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine (201-300 mg/day)
Number of subjects: 2000
Study 7961545 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine (> 300 mg/day)
Number of subjects: 2000
Study 7961545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 3054555 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic transfusions of frozen red cells
Number of subjects: 72
Study 3054555 — intervention group
Group type: COMPARATOR
Intervention: Red-cell transfusions only for medical or obstetric emergencies
Number of subjects: 72
Study 31755939 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically elevated levels of factor VIII activity
Number of subjects: 375000
Study 31755939 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically elevated levels of factor VIII antigen
Number of subjects: 375000
Study 31755939 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically elevated levels of factor XI activity
Number of subjects: 375000
Study 31755939 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased gamma (γ') fibrinogen
Number of subjects: 375000
Study 31755939 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated plateletcrit
Number of subjects: 375000